• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

喹扎替尼与颅脑脊髓照射联合治疗对伴有中枢神经系统受累的FMS样酪氨酸激酶3-内部串联重复阳性难治性急性髓系白血病的临床意义。

Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.

作者信息

Suga Makiko, Fukushima Kentaro, Ueda Tomoaki, Arai Yasuyuki, Nakagawa Shunsaku, Minami Yosuke, Toda Jun, Hino Akihisa, Fujita Jiro, Yokota Takafumi, Hosen Naoki

机构信息

Department of Hematology and Oncology Osaka University Graduate School of Medicine Suita Japan.

Department of Hematology and Oncology Kyoto University Hospital Kyoto Japan.

出版信息

Clin Case Rep. 2022 Feb 4;10(2):e05384. doi: 10.1002/ccr3.5384. eCollection 2022 Feb.

DOI:10.1002/ccr3.5384
PMID:35140970
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8815089/
Abstract

FMS-like tyrosine kinase 3-internal tandem duplication (-ITD) mutation-positive acute myeloid leukemia (AML) has a poor prognosis. We report the first case of successful bridge therapy of novel FLT3 inhibitor, quizartinib, to umbilical cord blood stem cell transplantation for -ITD-positive AML-primary induction failure patients with central nervous system involvement.

摘要

FMS样酪氨酸激酶3内部串联重复（-ITD）突变阳性的急性髓系白血病（AML）预后较差。我们报告了首例针对-ITD阳性AML伴中枢神经系统受累且初次诱导失败的患者，成功将新型FLT3抑制剂奎扎替尼用于桥接治疗至脐带血干细胞移植的病例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/517d/8815089/1a77e37b03ae/CCR3-10-e05384-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/517d/8815089/9486d405e01e/CCR3-10-e05384-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/517d/8815089/1a77e37b03ae/CCR3-10-e05384-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/517d/8815089/9486d405e01e/CCR3-10-e05384-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/517d/8815089/1a77e37b03ae/CCR3-10-e05384-g003.jpg

相似文献

1
Clinical implications of combination therapy with quizartinib and craniospinal irradiation for refractory acute myeloid leukemia positive for FMS-like tyrosine kinase 3-internal tandem duplication with central nervous system involvement.喹扎替尼与颅脑脊髓照射联合治疗对伴有中枢神经系统受累的FMS样酪氨酸激酶3-内部串联重复阳性难治性急性髓系白血病的临床意义。
Clin Case Rep. 2022 Feb 4;10(2):e05384. doi: 10.1002/ccr3.5384. eCollection 2022 Feb.
2
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.Quizartinib，一种 FLT3 抑制剂，作为复发或难治性急性髓系白血病患者的单药治疗：一项开放标签、多中心、单臂、2 期临床试验。
Lancet Oncol. 2018 Jul;19(7):889-903. doi: 10.1016/S1470-2045(18)30240-7. Epub 2018 May 31.
3
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.Quizartinib 联合化疗治疗新诊断的 FLT3 内部串联重复阳性急性髓系白血病患者（QuANTUM-First）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 May 13;401(10388):1571-1583. doi: 10.1016/S0140-6736(23)00464-6. Epub 2023 Apr 25.
4
Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.在原发性 FLT3-ITD AML 细胞中， quizartinib 联合 PI3K 抑制治疗可提高疗效。
Adv Biol Regul. 2023 Aug;89:100974. doi: 10.1016/j.jbior.2023.100974. Epub 2023 May 23.
5
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.每日给予复发或难治性急性髓系白血病患者quizartinib 的 I 期研究，无论 FMS 样酪氨酸激酶 3 内部串联重复状态如何。
J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783. Epub 2013 Sep 3.
6
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.在 QUANTUM-R 试验中，接受 Quizartinib 或挽救性化疗后行造血干细胞移植的伴有 FLT3-ITD 突变的复发/难治性急性髓系白血病患者的临床结局。
Transplant Cell Ther. 2021 Feb;27(2):153-162. doi: 10.1016/j.bbmt.2020.09.036. Epub 2020 Oct 2.
7
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
8
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Quizartinib 与挽救性化疗治疗复发或难治性 FLT3-ITD 急性髓系白血病（QuANTUM-R）：一项多中心、随机、对照、开放标签、3 期临床试验。
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
9
Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.在一项开放标签、2 期研究中，评估 quizartinib 在伴有 FLT3-ITD 阳性的复发/难治性急性髓系白血病的日本患者中的疗效和安全性。
Int J Hematol. 2019 Dec;110(6):665-674. doi: 10.1007/s12185-019-02727-6. Epub 2019 Aug 31.
10
Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.高三尖杉酯碱通过靶向 FLT3-AKT-c-Myc 通路与 quizartinib 在 FLT3-ITD 急性髓系白血病中协同作用。
Biochem Pharmacol. 2021 Jun;188:114538. doi: 10.1016/j.bcp.2021.114538. Epub 2021 Apr 6.

引用本文的文献

1
Therapeutics of acute myeloid leukemia with central nervous system involvement.伴有中枢神经系统受累的急性髓系白血病的治疗
Clin Hematol Int. 2025 Mar 11;7(1):40-46. doi: 10.46989/001c.131722. eCollection 2025.

本文引用的文献

1
A Relapsing Meningeal Acute Myeloid Leukaemia FLT3-ITD+ Responding to Gilteritinib.复发脑膜急性髓系白血病伴 FLT3-ITD 阳性患者对吉特替尼治疗有反应。
Chemotherapy. 2021;66(4):134-138. doi: 10.1159/000518356. Epub 2021 Aug 24.
2
Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.在 QUANTUM-R 试验中，接受 Quizartinib 或挽救性化疗后行造血干细胞移植的伴有 FLT3-ITD 突变的复发/难治性急性髓系白血病患者的临床结局。
Transplant Cell Ther. 2021 Feb;27(2):153-162. doi: 10.1016/j.bbmt.2020.09.036. Epub 2020 Oct 2.
3
Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?
在异体干细胞移植前，急性髓系白血病微小残留病灶导向治疗最有前途的靶点有哪些？
Haematologica. 2019 Aug;104(8):1521-1531. doi: 10.3324/haematol.2018.208587.
4
Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.在一项 1 期研究中，评估 quizartinib 在复发或难治性急性髓系白血病的日本患者中的安全性和药代动力学。
Int J Hematol. 2019 Dec;110(6):654-664. doi: 10.1007/s12185-019-02709-8. Epub 2019 Jul 29.
5
Availability of FLT3 inhibitors: how do we use them?FLT3 抑制剂的可及性：我们如何使用它们？
Blood. 2019 Aug 29;134(9):741-745. doi: 10.1182/blood.2019876821. Epub 2019 Jun 26.
6
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.Quizartinib 与挽救性化疗治疗复发或难治性 FLT3-ITD 急性髓系白血病（QuANTUM-R）：一项多中心、随机、对照、开放标签、3 期临床试验。
Lancet Oncol. 2019 Jul;20(7):984-997. doi: 10.1016/S1470-2045(19)30150-0. Epub 2019 Jun 4.
7
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.CYP3A 抑制剂对强效和选择性 FLT3 抑制剂 quizartinib 及其活性代谢物的药代动力学的影响。
Br J Clin Pharmacol. 2019 Sep;85(9):2108-2117. doi: 10.1111/bcp.14022. Epub 2019 Jul 23.
8
Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.精准医学和新型分子靶向治疗在急性髓系白血病中的应用：血液恶性肿瘤（HM）-SCREEN-Japan 01 的背景。
Int J Clin Oncol. 2019 Aug;24(8):893-898. doi: 10.1007/s10147-019-01467-1. Epub 2019 May 20.
9
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.维奈克拉可穿透脑脊液，对合并中枢神经系统受累的慢性淋巴细胞白血病可能有效。
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
10
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML.2b 期单药quizartinib 治疗 ITD 突变的复发/难治性 AML 的 2 种剂量方案研究。
Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.